KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Capital Leases (2020 - 2022)

Ginkgo Bioworks Holdings filings provide 3 years of Capital Leases readings, the most recent being $59.8 million for Q3 2022.

  • On a quarterly basis, Capital Leases rose 267.85% to $59.8 million in Q3 2022 year-over-year; TTM through Sep 2022 was $59.8 million, a 267.85% increase, with the full-year FY2021 number at $22.3 million, up 34.9% from a year prior.
  • Capital Leases hit $59.8 million in Q3 2022 for Ginkgo Bioworks Holdings, up from $51.5 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $59.8 million in Q3 2022 to a low of $16.3 million in Q3 2021.
  • Median Capital Leases over the past 3 years was $24.8 million (2021), compared with a mean of $32.3 million.
  • Biggest five-year swings in Capital Leases: surged 34.9% in 2021 and later soared 267.85% in 2022.
  • Ginkgo Bioworks Holdings' Capital Leases stood at $16.5 million in 2020, then skyrocketed by 34.9% to $22.3 million in 2021, then skyrocketed by 168.55% to $59.8 million in 2022.
  • The last three reported values for Capital Leases were $59.8 million (Q3 2022), $51.5 million (Q2 2022), and $27.3 million (Q1 2022) per Business Quant data.